Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, down from a net income of $32.7 million in Q1 2025, mainly due to the absence of a $50 million payment from Nestlé related to the VOWST sale. The company is progressing its live biotherapeutic pipeline, including SER-155 for immune checkpoint inhibitor-related enterocolitis and bloodstream infection prevention in blood cancer patients, and SER-603 for inflammatory bowel disease. Clinical data from an investigator-sponsored trial of SER-155 is expected soon, which could expand its therapeutic applications. Seres is actively seeking partnerships and funding to support further development and extend its cash runway beyond Q3 2026.
The global Edge AI software market is projected to grow from $2.40 billion in 2025 to $8.89 billion by 2031, at a CAGR of 24.4%. This growth is fueled by rising demand for real-time AI decision-making, localized data processing, and intelligent edge ...
Leon Aryah Lewis, a Los Angeles-based mystic, has published his debut book "Inside Out: A Journey of the Soul," which he wrote three decades ago but only recently released. The book blends memoir and spiritual reflections, exploring themes like reinc...
A director at Flywire has sold 6,524 shares of the company's stock, totaling approximately $92,000. This insider sale may indicate personal financial decisions or a shift in confidence, which investors often watch closely. While not necessarily a sig...
Elevance Health reported mixed second-quarter results with adjusted EPS of $7.45 beating estimates, but down 15.7% year-over-year, and a 1.5% decline in medical membership. Operating revenues grew slightly to $49.8 billion, driven by its CarelonRx di...
Teradata is expanding into AI with its new Autonomous Knowledge Platform, prompting RBC Capital to raise its price target to $34 while maintaining a neutral "Sector Perform" rating. Despite optimism about growth in enterprise AI, the stock appears ov...
